首页> 外文期刊>Experimental & Molecular Pathology >Activation of PPAR-gamma reduces HPA axis activity in diabetic rats by up-regulating PI3K expression
【24h】

Activation of PPAR-gamma reduces HPA axis activity in diabetic rats by up-regulating PI3K expression

机译:PPAR-γ的激活通过上调PI3K表达来降低糖尿病大鼠的HPA轴活性

获取原文
获取原文并翻译 | 示例
       

摘要

Increased hypothalamus-pituitary-adrenal axis (HPA) activity in diabetes is strongly associated with several morbidities noted in patients with the disease. We previously demonstrated that hyperactivity of HPA axis under diabetic conditions is associated with up-regulation of adrenocorticotrophic hormone (ACTH) receptors (MC2R) in adrenal and down-regulation of glucocorticoid receptors (GR and MR) in pituitary. This study investigates the role of peroxisome proliferator-activated receptor (PPAR)-gamma in HPA axis hyperactivity in diabetic rats. Diabetes was induced by intravenous injection of alloxan into fasted rats. The PPAR-gamma agonist rosiglitazone and/or PI3K inhibitor wortmannin were administered daily for 18 consecutive days, starting 3 days after diabetes induction. Plasma ACTH and corticosterone were evaluated by radioimmunoassay, while intensities of MC2R, proopiomelanocortin (POMC), GR, MR, PI3K p110 alpha and PPAR-gamma were assessed using immunohistochemistry. Rosiglitazone treatment inhibited adrenal hypertrophy and hypercorticoidism observed in diabetic rats. Rosiglitazone also significantly reversed the diabetes-induced increase in the MC2R expression in adrenal cortex. We noted that rosiglitazone reduced the number of corticotroph cells and inhibited both anterior pituitary POMC expression and plasma ACTH levels. Furthermore, rosiglitazone treatment was unable to restore the reduced expression of GR and MR in the anterior pituitary of diabetic rats. Rosiglitazone increased the number of PPAR-gamma(+) cells and expression of PI3K p110 alpha in both anterior pituitary and adrenal cortex of diabetic rats. In addition, wortmannin blocked the ability of rosiglitazone to restore corticotroph cell numbers, adrenal hypertrophy and plasma corticosterone levels in diabetic rats. In conclusion, our findings revealed that rosiglitazone down-regulates HPA axis hyperactivity in diabetic rats via a mechanism dependent on PI3K activation in pituitary and adrenal glands. (C) 2016 Elsevier Inc. All rights reserved.
机译:糖尿病患者下丘脑-垂体-肾上腺轴(HPA)活性的增强与该病患者中注意到的几种发病率密切相关。我们先前证明,在糖尿病条件下,HPA轴的过度活跃与肾上腺的肾上腺皮质营养激素(ACTH)受体(MC2R)的上调和垂体中糖皮质激素受体(GR和MR)的下调有关。这项研究调查了过氧化物酶体增殖物激活受体(PPAR)-γ在糖尿病大鼠HPA轴亢进中的作用。通过向禁食的大鼠静脉内注射四氧嘧啶诱导糖尿病。从诱导糖尿病后3天开始,每天连续18天每天服用PPAR-γ激动剂罗格列酮和/或PI3K抑制剂渥曼青霉素。通过放射免疫分析评估血浆ACTH和皮质酮,同时使用免疫组织化学评估MC2R,原黑皮质素(POMC),GR,MR,PI3K p110α和PPAR-γ的强度。罗格列酮治疗可抑制在糖尿病大鼠中观察到的肾上腺肥大和皮质激素过多。罗格列酮还显着逆转了糖尿病引起的肾上腺皮质MC2R表达增加。我们注意到罗格列酮减少了皮质营养细胞的数量并抑制了垂体前叶POMC表达和血浆ACTH水平。此外,罗格列酮治疗不能恢复糖尿病大鼠垂体前叶GR和MR的降低表达。罗格列酮增加了糖尿病大鼠垂体前叶和肾上腺皮质中PPAR-γ(+)细胞的数量和PI3K p110α的表达。此外,渥曼青霉素还阻断了罗格列酮恢复糖尿病大鼠皮质营养细胞数量,肾上腺肥大和血浆皮质酮水平的能力。总之,我们的发现表明罗格列酮通过依赖于垂体和肾上腺中PI3K激活的机制下调了糖尿病大鼠中HPA轴的过度活动。 (C)2016 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号